Nice one, R&P. I said on ST about 5 min ago that no timeline projected "deadline" has been missed since J. Garner took over. Maybe an old Novogen drug bit the dust, but that wasn't his fault.
69 trials for DIPG and I'm betting on an upset. For instance, ZIOP has almost 50% intso ownership and about 200 million sh outstanding. They're #21 on the list of trials. Large, well-respected insto backers of them are MISSING THE BOAT with respect to Kazia. I don't care, as those funds don't manage any of my money.
Just saying, when good news here comes out there will be a rush to get into the club and the doorman will be irrelevant.
Almost forgot the link:
https://clinicaltrials.gov/ct2/results?cond=dipg&term=&cntry=US&state=&city=&dist=#wrapper
